Status:
ENROLLING_BY_INVITATION
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Lead Sponsor:
Allogene Therapeutics
Conditions:
Hematologic Malignancies
Solid Tumors
Eligibility:
All Genders
Brief Summary
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infus...
Eligibility Criteria
Inclusion
- Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study
Exclusion
- Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
Key Trial Info
Start Date :
January 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2039
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06925685
Start Date
January 31 2025
End Date
January 1 2039
Last Update
April 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Circuit Clinical
Buffalo, New York, United States, 14203